Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Male Urogenital Diseases: early-phase trial registry
3 of 3 indexed Male Urogenital Diseases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Male Urogenital Diseases: 3 US clinical trials tracked, 3 recruiting.
Male Urogenital Diseases is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is VA Greater Los Angeles Healthcare System, running 1 of these trials.
Enrollment posture brief
Registry condition male-urogenital-diseases
OPEN 3 | RECR 100% | LATE 1 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Male Urogenital Diseases lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Male Urogenital Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Male Urogenital Diseases is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Pathos AI
NCT06785636
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
NCT06706921
Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures
Wake Forest University Health Sciences
NCT03258658
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Male Urogenital Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Male Urogenital Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Male Urogenital Diseases page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Male Urogenital Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- VA Greater Los Angeles Healthcare System sponsors the most Male Urogenital Diseases trials on record, review their full trial history before evaluating a specific study. See VA Greater Los Angeles Healthcare System's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Male Urogenital Diseases condition card totals 3 registered trials; most-linked intervention 18F-Fluciclovine PET/CT Scan; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.